365 related articles for article (PubMed ID: 30181331)
1. We're Not "DON" Yet: Optimal Dosing and Prodrug Delivery of
Lemberg KM; Vornov JJ; Rais R; Slusher BS
Mol Cancer Ther; 2018 Sep; 17(9):1824-1832. PubMed ID: 30181331
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 6-Diazo-5-oxo-l-norleucine (DON) Prodrugs with Enhanced CSF Delivery in Monkeys: A Potential Treatment for Glioblastoma.
Rais R; Jančařík A; Tenora L; Nedelcovych M; Alt J; Englert J; Rojas C; Le A; Elgogary A; Tan J; Monincová L; Pate K; Adams R; Ferraris D; Powell J; Majer P; Slusher BS
J Med Chem; 2016 Sep; 59(18):8621-33. PubMed ID: 27560860
[TBL] [Abstract][Full Text] [Related]
3. Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug.
Rais R; Lemberg KM; Tenora L; Arwood ML; Pal A; Alt J; Wu Y; Lam J; Aguilar JMH; Zhao L; Peters DE; Tallon C; Pandey R; Thomas AG; Dash RP; Seiwert T; Majer P; Leone RD; Powell JD; Slusher BS
Sci Adv; 2022 Nov; 8(46):eabq5925. PubMed ID: 36383674
[TBL] [Abstract][Full Text] [Related]
4. Model studies towards prodrugs of the glutamine antagonist 6-diazo-5-oxo-l-norleucine (DON) containing a diazo precursor.
Gao RD; Hin N; Prchalová E; Pal A; Lam J; Rais R; Slusher BS; Tsukamoto T
Bioorg Med Chem Lett; 2021 Oct; 50():128321. PubMed ID: 34400301
[TBL] [Abstract][Full Text] [Related]
5. Discovery of
Novotná K; Tenora L; Prchalová E; Paule J; Alt J; Veeravalli V; Lam J; Wu Y; Šnajdr I; Gori S; Mettu VS; Tsukamoto T; Majer P; Slusher BS; Rais R
J Med Chem; 2023 Nov; 66(22):15493-15510. PubMed ID: 37949450
[TBL] [Abstract][Full Text] [Related]
6. Tumor-Targeted Delivery of 6-Diazo-5-oxo-l-norleucine (DON) Using Substituted Acetylated Lysine Prodrugs.
Tenora L; Alt J; Dash RP; Gadiano AJ; Novotná K; Veeravalli V; Lam J; Kirkpatrick QR; Lemberg KM; Majer P; Rais R; Slusher BS
J Med Chem; 2019 Apr; 62(7):3524-3538. PubMed ID: 30892035
[TBL] [Abstract][Full Text] [Related]
7. A redox-responsive prodrug for tumor-targeted glutamine restriction.
Prange CJ; Sayed NYB; Feng B; Goepfert C; Trujillo DO; Hu X; Tang L
J Control Release; 2024 Apr; 368():251-264. PubMed ID: 38403173
[TBL] [Abstract][Full Text] [Related]
8. Novel Glutamine Antagonist JHU395 Suppresses MYC-Driven Medulloblastoma Growth and Induces Apoptosis.
Pham K; Maxwell MJ; Sweeney H; Alt J; Rais R; Eberhart CG; Slusher BS; Raabe EH
J Neuropathol Exp Neurol; 2021 Mar; 80(4):336-344. PubMed ID: 33712838
[TBL] [Abstract][Full Text] [Related]
9. Phase II evaluation of DON (6-diazo-5-oxo-L-norleucine) in patients with advanced colorectal carcinoma.
Lynch G; Kemeny N; Casper E
Am J Clin Oncol; 1982 Oct; 5(5):541-3. PubMed ID: 7180833
[TBL] [Abstract][Full Text] [Related]
10. Unbiased Metabolic Profiling Predicts Sensitivity of High MYC-Expressing Atypical Teratoid/Rhabdoid Tumors to Glutamine Inhibition with 6-Diazo-5-Oxo-L-Norleucine.
Wang SZ; Poore B; Alt J; Price A; Allen SJ; Hanaford AR; Kaur H; Orr BA; Slusher BS; Eberhart CG; Raabe EH; Rubens JA
Clin Cancer Res; 2019 Oct; 25(19):5925-5936. PubMed ID: 31300448
[TBL] [Abstract][Full Text] [Related]
11. Reviving Lonidamine and 6-Diazo-5-oxo-L-norleucine to Be Used in Combination for Metabolic Cancer Therapy.
Cervantes-Madrid D; Romero Y; Dueñas-González A
Biomed Res Int; 2015; 2015():690492. PubMed ID: 26425550
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and phase I study of intravenous DON (6-diazo-5-oxo-L-norleucine) in children.
Sullivan MP; Nelson JA; Feldman S; Van Nguyen B
Cancer Chemother Pharmacol; 1988; 21(1):78-84. PubMed ID: 3342470
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of 6-diazo-5-oxo-L-norleucine (DON, NSC-7365) in advanced large bowel carcinoma.
Rubin J; Sorensen S; Schutt AJ; van Hazel GA; O'Connell MJ; Moertel CG
Am J Clin Oncol; 1983 Jun; 6(3):325-6. PubMed ID: 6846250
[No Abstract] [Full Text] [Related]
14. Uptake of glutamine antimetabolites 6-diazo-5-oxo-L-norleucine (DON) and acivicin in sensitive and resistant tumor cell lines.
Huber KR; Rosenfeld H; Roberts J
Int J Cancer; 1988 May; 41(5):752-5. PubMed ID: 3366493
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of 6-diazo-5-oxo-L-norleucine (DON).
Sklaroff RB; Casper ES; Magill GB; Young CW
Cancer Treat Rep; 1980; 64(12):1247-51. PubMed ID: 7471114
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of 6-diazo-5-oxo-L-norleucine (DON) administered by 5-day courses.
Earhart RH; Koeller JM; Davis HL
Cancer Treat Rep; 1982 May; 66(5):1215-7. PubMed ID: 7083223
[TBL] [Abstract][Full Text] [Related]
17. DON of Hope: Starving Pancreatic Cancer by Glutamine Antagonism.
Pillai R; Papagiannakopoulous T
Cancer Res; 2024 Feb; 84(3):349-350. PubMed ID: 38117482
[TBL] [Abstract][Full Text] [Related]
18. Antagonizing Bcl-2 family members sensitizes neuroblastoma and Ewing's sarcoma to an inhibitor of glutamine metabolism.
Olsen RR; Mary-Sinclair MN; Yin Z; Freeman KW
PLoS One; 2015; 10(1):e0116998. PubMed ID: 25615615
[TBL] [Abstract][Full Text] [Related]
19. The role of glutamine and glucose analogues in metabolic inhibition of human myeloid leukaemia in vitro.
Griffiths M; Keast D; Patrick G; Crawford M; Palmer TN
Int J Biochem; 1993 Dec; 25(12):1749-55. PubMed ID: 8138012
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia-activated glutamine antagonist prodrug combined with combretastatin A4 nanoparticles for tumor-selective metabolic blockade.
Zheng M; Xu H; Huang Y; Sun J; Zhang H; Lv Z; Liu Z; Tang Z; Chen X
J Control Release; 2024 Jan; 365():480-490. PubMed ID: 38040341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
